Clinical Trials
9 trialsNCT04510311 2025-01-10
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT04614766 2024-04-29
SPORE-3
University of Iowa
Phase 1/2 Withdrawn
NCT03044977 2023-08-16
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT04831567 2022-05-19
MIBNET
AC Camargo Cancer Center
Phase 2 Withdrawn
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT00037869 2018-10-31
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01099228 2016-07-21
Combination Targeted Radiotherapy in Neuroendocrine Tumors
University of Iowa
Phase NA Completed
NCT00458952 2016-07-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01941849 2015-12-21
VIBRaNT
University College, London
Phase 1 Withdrawn